Sign In
Buy RPRX
$53.57
+0.610 (+1.15%)
At Close: Jun 22, 2026
Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock
04:02am, Sunday, 25'th Jan 2026
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 69,582 shares of the firm's stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of
Allstate Corp Acquires New Stake in Royalty Pharma PLC $RPRX
03:34am, Saturday, 24'th Jan 2026
Allstate Corp bought a new position in Royalty Pharma PLC (NASDAQ: RPRX) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fun
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
04:15pm, Tuesday, 20'th Jan 2026
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 202
Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock
05:00am, Thursday, 15'th Jan 2026
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of the stock in a transaction on Friday, January 9th. The shares were sold at an average price of $40.78, for
Eastern Bank Boosts Stake in Royalty Pharma PLC $RPRX
04:48am, Wednesday, 14'th Jan 2026
Eastern Bank lifted its holdings in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 1,368.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Co
Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:05pm, Tuesday, 13'th Jan 2026
Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
12:26pm, Monday, 12'th Jan 2026
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva's an
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
07:15am, Monday, 12'th Jan 2026
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments. Pablo Legorreta, Royalty Pharm
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
05:15pm, Sunday, 11'th Jan 2026
NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEV
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
05:00pm, Sunday, 11'th Jan 2026
PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: R
Royalty Pharma Announces Dividend Increase
08:30am, Friday, 09'th Jan 2026
NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A or
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
01:52am, Friday, 09'th Jan 2026
Pharmaceuticals giant, Merck and Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32
Your $10 Billion Investing Playbook for 2026
12:00am, Tuesday, 06'th Jan 2026
Where Buffett's former heir apparent will invest $10 billion… exactly how to follow this blueprint… defense, aerospace, healthcare, energy, minerals, frontier tech… investment ideas from ETFs to
Generali Asset Management SPA SGR Grows Stock Holdings in Royalty Pharma PLC $RPRX
05:34am, Monday, 05'th Jan 2026
Generali Asset Management SPA SGR grew its holdings in Royalty Pharma PLC (NASDAQ: RPRX) by 7,752.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commissi
What's Going On With Royalty Pharma Stock Wednesday?
10:47am, Wednesday, 31'st Dec 2025
Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.
